# AbbVie hikes 2026 outlook as Skyrizi, Rinvoq offset Humira slump.

*business · news · 2026-04-29 · Seeking Alpha*

## Key points

- AbbVie raised its 2026 full-year earnings outlook due to strong Skyrizi and Rinvoq performance.
- Skyrizi and Rinvoq sales growth is now offsetting the decline in former best-seller Humira.
- AbbVie reported a Q1 2026 revenue that surpassed analyst expectations.
- AbbVie shares rose approximately 2% in premarket trading after the updated guidance announcement.

**Companies:** AbbVie Inc.
**Countries:** United States

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4581506-abbvie-stock-gains-2026-guidance-hike)

---

Canonical: https://newsio.io/n/05d584b7-e9f3-4a74-84a3-d3181f677654/abbvie-hikes-2026-outlook-as-skyrizi-rinvoq-offset-humira-slump
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works